Advertisement
Mayo Clinic Proceedings Home

Techniques of Immunosuppression After Cardiac Transplantation

      Modulation of the normal immune response is the major challenge for successful organ transplantation. Cardiac allograft rejection is primarily the result of activation of T cells. Most currently used immunosuppressive agents mainly affect the T-cell-mediated limb of the immune system. Immunosuppressive strategies can be considered to have three goals: (1) prophylaxis against rejection early after cardiac transplantation, (2) long-term maintenance prophylaxis, and (3) treatment of acute rejection. The extent of immunosuppression needed varies with the time after transplantation and the rejection profile of the individual patient. The goal is to provide sufficient immunosuppression to retard rejection without causing undesirable side effects, including infection and neoplasms.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

        • Woodley SL
        • Renlund DG
        • O'Connell JB
        • Bristow MR
        Immunosuppression following cardiac transplantation.
        Cardiol Clin. February 1990; 8: 83-96
        • Duquesnoy RJ
        • Cramer DV
        Immunologic mechanisms of cardiac transplant rejection.
        Cardiovasc Clin. 1990; 20: 87-103
      1. Dupont B Immunobiology of HLA. Springer-Verlag, New York1989
        • Yacoub M
        • Festenstein H
        • Doyle P
        • Martin M
        • McCloskey D
        • Awad J
        • Gamba A
        • Khaghani A
        • Holmes J
        The influence of HLA matching in cardiac allograft recipients receiving cyclosporine and azathioprine.
        Transplant Proc. 1987; 19: 2487-2489
        • Frist WH
        • Oyer PE
        • Baldwin JC
        • Stinson EB
        • Shumway NE
        HLA compatibility and cardiac transplant recipient survival.
        Ann Thorac Surg. 1987; 44: 242-246
        • Raffoux C
        • Mayor V
        • Cabrol C
        • Busson M
        • Hors J
        • Colombani J
        The influence of HLA matching in cardiac allograft recipients in a single center.
        Transplant Proc. 1987; 19: 3559-3560
        • Zerbe T
        • Arena V
        • Kormos R
        • Colson Y
        • Griffith B
        • Hardesty R
        Role of major histocompatibility complex (HLA) matching in cardiac allograft rejection.
        Transplant Proc. 1988; 20: 74-75
        • Pfeffer PF
        • Foerster A
        • Frøysaker T
        • Thorsby E
        Correlation between HLA-DR mismatch and rejection episodes in cardiac transplantation.
        Transplant Proc. 1987; 19: 691-692
        • DiSesa VJ
        • Kuo PC
        • Horvath KA
        • Mudge GH
        • Collins Jr, JJ
        • Cohn LH
        HLA histocompatibility affects cardiac transplant rejection and may provide one basis for organ allocation.
        Ann Thorac Surg. 1990; 49: 220-223
        • Chan GLC
        • Gruber SA
        • Skjei KL
        • Canafax DM
        Principles of immunosuppression.
        Crit Care Clin. October 1990; 6: 841-892
        • Kahan BD
        Cyclosporine.
        N Engl J Med. 1989; 321: 1725-1738
        • Reed JC
        • Prystowsky MB
        • Nowell PC
        Regulation of gene expression in lectin-stimulated or lymphokine-stimulated T lymphocytes: effects of cyclosporine.
        Transplantation. 1988; 46: 85S-89S
        • Macoviak JA
        • Oyer PE
        • Stinson EB
        • Jamieson SW
        • Baldwin JC
        • Shumway NE
        Four-year experience with cyclosporine for heart and heart-lung transplantation.
        Transplant Proc. 1985; 17: 97-101
        • Ptachcinski RJ
        • Venkataramanan R
        • Burckart GJ
        Clinical pharmacokinetics of cyclosporin.
        Clin Pharmacokinet. 1986; 11: 107-132
        • Combalbert J
        • Fabre I
        • Fabre G
        • Dalet I
        • Derancourt J
        • Cano JP
        • Maurel P
        Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily.
        Drug Metab Dispos. 1989; 17: 197-207
        • Lindholm A
        • Henricsson S
        • Lind M
        • Dahlqvist R
        Intraindividual variability in the relative systemic availability of cyclosporin after oral dosing.
        Eur J Clin Pharmacol. 1988; 34: 461-464
      2. Critical issues in cyclosporine monitoring: report of the Task Force on Cyclosporine Monitoring.
        Clin Chem. 1987; 33: 1269-1288
        • Myers BD
        • Ross J
        • Newton L
        • Luetscher J
        • Perlroth M
        Cyclosporine-associated chronic nephropathy.
        N Engl J Med. 1984; 311: 699-705
        • Grattan MT
        • Moreno-Cabral CE
        • Starnes VA
        • Oyer PE
        • Stinson EB
        • Shumway NE
        Eight-year results of cyclosporine-treated patients with cardiac transplants.
        J Thorac Cardiovasc Surg. 1990; 99: 500-509
        • Conte G
        • Dal Canton A
        • Sabbatini M
        • Napodano P
        • De Nicola L
        • Gigliotti G
        • Fuiano G
        • Testa A
        • Esposito C
        • Russo D
        • Andreucci VE
        Acute cyclosporine renal dysfunction reversed by dopamine infusion in healthy subjects.
        Kidney Int. 1989; 36: 1086-1092
        • Bach JF
        The Mode of Action of Immunosuppressive Agents. North-Holland Publishing Company, Amsterdam1975
        • Chan GLC
        • Erdmann GR
        • Gruber SA
        • Stock P
        • Chen S
        • Ascher NL
        • Canafax DM
        Pharmacokinetics of 6-thiouric acid and 6-mercaptopurine in renal allograft recipients after oral administration of azathioprine.
        Eur J Clin Pharmacol. 1989; 36: 265-271
        • Renlund DG
        • O'Connell JB
        • Gilbert EM
        • Watson FS
        • Bristow MR
        Feasibility of discontinuation of corticosteroid maintenance therapy in heart transplantation.
        J Heart Transplant. 1987; 6: 71-78
        • Cosimi AB
        Antilymphocyte globulin and monoclonal antibodies.
        in: Morris PJ Kidney Transplantation: Principles and Practice. Third edition. WB Saunders Company, Philadelphia1988: 343-369
        • Todd PA
        • Brogden RN
        Muromonab CD3: a review of its pharmacology and therapeutic potential.
        Drugs. 1989; 37: 871-899
        • Bach J-F
        • Chatenoud L
        Immunologic monitoring of Orthoclone OKT3-treated patients: the problem of antimonoclonal immune response.
        Transplant Proc. 1987; 19: 17-20
        • Emmons C
        • Smith J
        • Flanigan M
        Cerebrospinal fluid inflammation during OKT3 therapy (letter to the editor).
        Lancet. 1986; 2: 510-511
        • Goldstein G
        • Fuccello AJ
        • Norman DJ
        • Shield III, CF
        • Colvin RB
        • Cosimi AB
        OKT3 monoclonal antibody plasma levels during therapy and the subsequent development of host antibodies to OKT3.
        Transplantation. 1986; 42: 507-511
        • Ortho Multicenter Transplant Study Group
        A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants.
        N Engl J Med. 1985; 313: 337-342
        • First MR
        • Schroeder TJ
        • Hurtubise PE
        • Mansour ME
        • Penn I
        • Munda R
        • Balistreri WF
        • Alexander JW
        • Melvin DB
        • Fidler JP
        • Ryckman FC
        • Brunson ME
        Immune monitoring during retreatment with OKT3.
        Transplant Proc. 1989; 21: 1753-1754
        • Gilbert EM
        • Eiswirth CC
        • Renlund DG
        • Menlove RL
        • DeWitt CW
        • Freedman LA
        • Herrick CM
        • Gay WA
        • Bristow MR
        Use of Orthoclone OKT3 monoclonal antibody in cardiac transplantation: early experience with rejection prophylaxis and treatment of refractory rejection.
        Transplant Proc. 1987; 19: 45-53
        • Strober S
        • Modry DL
        • Hoppe RT
        • Pennock JL
        • Bieber CP
        • Holm BI
        • Jamieson SW
        • Stinson EB
        • Schroder J
        • Suomalainen H
        • Kaplan HS
        Induction of specific unresponsiveness to heart allografts in mongrel dogs treated with total lymphoid irradiation and anti-thymocyte globulin.
        J Immunol. 1984; 132: 1013-1018
        • Rynasiewicz JJ
        • Sutherland DER
        • Kawahara K
        • Najarian JS
        Total lymphoid irradiation: critical timing and combination with cyclosporin A for immunosuppression in a rat heart allograft model.
        J Surg Res. 1981; 30: 365-371
        • Levin B
        • Bohannon L
        • Warvariv V
        • Bry W
        • Collins G
        Total lymphoid irradiation (TLI) in the cyclosporine era—use of TLI in resistant cardiac allograft rejection.
        Transplant Proc. 1989; 21: 1793-1795
        • Frist WH
        • Winterland AW
        • Gerhardt EB
        • Merrill WH
        • Atkinson JB
        • Eastburn TE
        • Stewart JR
        • Eisert DR
        Total lymphoid irradiation in heart transplantation: adjunctive treatment for recurrent rejection.
        Ann Thorac Surg. 1989; 48: 863-864
        • Morris RE
        • Hoyt EG
        • Murphy MP
        • Shorthouse R
        Immunopharmacology of FK-506.
        Transplant Proc. 1989; 21: 1042-1044
        • Thomson AW
        FK-506—how much potential?.
        Immunol Today. 1989; 10: 6-9
        • Starzl TE
        • Todo S
        • Fung J
        • Demetris AJ
        • Venkataramanan R
        • Jain A
        FK 506 for liver, kidney, and pancreas transplantation.
        Lancet. 1989; 2: 1000-1004
        • Ochiai T
        • Sakamoto K
        • Gunji Y
        • Hamaguchi K
        • Isegawa N
        • Suzuki T
        • Shimada H
        • Hayashi H
        • Yasumoto A
        • Asano T
        • Isono K
        Effects of combination treatment with FK506 and cyclosporine on survival time and vascular changes in renal-allograft-recipient dogs.
        Transplantation. 1989; 48: 193-197
        • Armitage JM
        • Kormos RL
        • Griffith BP
        • Hardesty RL
        • Flicker FJ
        • Stuart RS
        • Marrone GC
        • Todo S
        • Fung J
        • Starzl TE
        A clinical trial of FK 506 as primary and rescue immunosuppression in cardiac transplantation.
        Transplant Proc. 1991; 23: 1149-1152
        • Kimball PM
        • Kerman RH
        • Kahan BD
        Production of synergistic but nonidentical mechanisms of immunosuppression by rapamycin and cyclosporine.
        Transplantation. 1991; 51: 486-490
        • Costanzo-Nordin MR
        • Grusk BB
        • Silver MA
        • Sobotka PA
        • Winters GL
        • O'Connell JB
        • Pifarré R
        • Robinson JA
        Reversal of recalcitrant cardiac allograft rejection with methotrexate.
        Circulation. 1988; 78: III47-III57
        • Olsen SL
        • O'Connell JB
        • Bristow MR
        • Renlund DG
        Methotrexate as an adjunct in the treatment of persistent mild cardiac allograft rejection.
        Transplantation. 1990; 50: 773-775
        • Crandall BG
        • Gilbert EM
        • Renlund DG
        • Menlove RL
        • Herrick CM
        • Holland CS
        • Hagan ME
        • Rasmussen LG
        • Karwande SV
        • O'Connell JB
        • Bristow MR
        A randomized trial of the immunosuppressive efficacy of vincristine in cardiac transplantation.
        Transplantation. 1990; 50: 34-38
        • O'Connell JB
        • Bristow MR
        • Rasmussen LG
        • Ratkovec RM
        • Gay Jr, WA
        • Jones KW
        • Renlund DG
        Cardiac allograft function with corticosteroid-free maintenance immunosuppression.
        Circulation. 1990; 82: IV318-IV321
        • Steinman TI
        • Zimmerman CE
        • Monaco AP
        • Brown RS
        • Yager HM
        • Clive DM
        • Ransil BJ
        Steroids can be stopped in kidney transplant recipients.
        Transplant Proc. 1981; 13: 323-327
        • O'Connell P
        • d'Apice A
        • Walker R
        • Francis D
        • Kincaid-Smith P
        Cessation of steroids in renal allograft recipients on combined cyclosporine A, azathioprine, and prednisolone.
        Transplant Proc. 1988; 20: 11-13